On October 14, 2022 Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on oncology, reported that it has received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47) bispecific antibody being developed for patients with small cell lung cancer (SCLC) and other neuroendocrine cancers (Press release, Phanes Therapeutics, OCT 14, 2022, View Source [SID1234622036]). PT217 has recently been granted an orphan drug designation by the FDA for the treatment of SCLC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This is the third program in our pipeline that has received IND clearance by FDA this year, which is an important milestone for Phanes and a record for a biotech company of our size. The opportunity to bring this potential first-in-class bispecific antibody to cancer patients who have such a high unmet medical need is at the core of what drives us as a company," said Dr. Ming Wang, Founder and CEO. "With a strong pipeline targeting both the adaptive and innate immunity and the bispecific antibody technology platforms we have built, Phanes is well positioned to make important impacts in delivering innovative cancer therapies."
The Phase I study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of PT217 in subjects with advanced or refractory cancers. Patients with the following tumor types will be eligible for screening: unresectable SCLC, large cell neuroendocrine cancer (LCNEC), neuroendocrine prostate cancer (NEPC) and gastroenteropancreatic neuroendocrine tumors (GEP-NET). Subjects must have progressed after standard therapy (at least one line of platinum-based chemotherapy with or without immune checkpoint inhibitor for SCLC) or standard therapy has proven to be ineffective, intolerable or was considered inappropriate.
SCLC is an aggressive pulmonary carcinoma hallmarked by high early mortality rates and significant morbidities throughout the disease’s progression. The 1-year survival of patients with SCLC is only 32.9%, with survival steadily decreasing with only 10.7% of patients surviving 3 years.
Phanes current clinical programs include: PT199, a differentiated anti-CD73 monoclonal antibody, enrolling at 3 US study sites and PT886, an anti-Claudin 18.2/anti-CD47 bispecific antibody, which is in study startup at The University of Texas MD Anderson Cancer Center, Houston, TX.